Dose Optimization of BIIB107, an Anti-Alpha-4 Integrin Monoclonal Antibody, Through Population Pharmacokinetic and
Marie Toukam1, Negin Karimian2, Eris Bame3
1Clinical Pharmacology and Pharmacometrics, Biogen, Cambridge, MA, USA.
BIIB107 is a recombinant, humanized monoclonal antibody targeting α4 integrin receptors, exhibiting a high binding affinity and strong receptor engagement potential in preclinical models, designed to prevent lymphocyte trafficking in multiple sclerosis (MS). This study aimed to characterize its pharmacokinetics (PK) and pharmacokinetic-pharmacodynamic (PK-PD) relationship using model-based approaches to inform dose optimization. A Phase 1 study (NCT04593121) was conducted in 76 healthy volunteers who received single ascending doses intravenously or subcutaneously (SC), along with multiple ascending doses SC. Population PK and PK-PD models were developed to quantify BIIB107 disposition and its effect on α4 integrin receptor saturation. A sigmoidal Emax model was used to characterize the concentration-effect relationship, and Monte Carlo simulations assessed dosing strategies for sustained α4 integrin engagement. BIIB107 exhibited nonlinear, target-mediated clearance, best described by a two-compartment model with first-order absorption and Michaelis-Menten elimination. Body weight was included in the model using allometric scaling on clearance and volume of distribution-related parameters. In a 70-kg subject, key PK parameters included clearance, 7.28 mL/h; central and peripheral compartment Vd, 3.01 and 1.18 L; terminal half-life 19.3 days; and SC bioavailability 73.8%. PK-PD analysis demonstrated dose-dependent α4 integrin saturation, with an EC50 of 0.376 µg/mL. Simulations showed that 450 mg SC every 8 weeks maintained sustained α4 integrin saturation ≥70%, the therapeutic threshold for efficacy, supporting this regimen for investigation in MS patients. These findings emphasize the value of model-informed drug development in optimizing therapeutic monoclonal antibody doses and support BIIB107's further clinical advancement.
BIIB107 is a recombinant, humanized monoclonal antibody targeting α4 integrin receptors, exhibiting a high binding affinity and strong receptor engagement potential in preclinical models, designed to prevent lymphocyte trafficking in multiple sclerosis (MS). This study aimed to characterize its pharmacokinetics (PK) and pharmacokinetic-pharmacodynamic (PK-PD) relationship using model-based approaches to inform dose optimization. A Phase 1 study (NCT04593121) was conducted in 76 healthy volunteers who received single ascending doses intravenously or subcutaneously (SC), along with multiple ascending doses SC. Population PK and PK-PD models were developed to quantify BIIB107 disposition and its effect on α4 integrin receptor saturation. A sigmoidal Emax model was used to characterize the concentration-effect relationship, and Monte Carlo simulations assessed dosing strategies for sustained α4 integrin engagement. BIIB107 exhibited nonlinear, target-mediated clearance, best described by a two-compartment model with first-order absorption and Michaelis-Menten elimination. Body weight was included in the model using allometric scaling on clearance and volume of distribution-related parameters. In a 70-kg subject, key PK parameters included clearance, 7.28 mL/h; central and peripheral compartment Vd, 3.01 and 1.18 L; terminal half-life 19.3 days; and SC bioavailability 73.8%. PK-PD analysis demonstrated dose-dependent α4 integrin saturation, with an EC50 of 0.376 µg/mL. Simulations showed that 450 mg SC every 8 weeks maintained sustained α4 integrin saturation ≥70%, the therapeutic threshold for efficacy, supporting this regimen for investigation in MS patients. These findings emphasize the value of model-informed drug development in optimizing therapeutic monoclonal antibody doses and support BIIB107's further clinical advancement.
More Related Videos
04:15Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
Published on: February 2, 2024
08:17A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
Published on: August 15, 2019
Related Concept Videos
01:12Analysis of Population Pharmacokinetic Data
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
01:20Measurement of Bioavailability: Pharmacodynamic Methods
01:13Physiological Pharmacokinetic Models: Assumption with Protein Binding
01:20Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
01:22Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
To quantify the extent of bioavailability, pharmacologists often use a parameter called .